Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome

• Published in: Neuropsychiatric disease and treatment Vol. 11; no. default; pp. 865 - 872
• Main Authors: Akyol, Esra Soydaş, Albayrak, Yakup, Beyazyüz, Murat, Aksoy, Nurkan, Kuloglu, Murat, Hashimoto, Kenji
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2015; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Age; Analysis; Attention-deficit hyperactivity disorder; Brain research; Brain-derived neurotrophic factor; Care and treatment; Chronic illnesses; Complications and side effects; Drug dosages; Education; Hospitals; Mental depression; Mental disorders; Neurosciences; Neurotrophic factors; Neurotrophic functions; Original Research; Patients; Psychiatry; Psychotropic drugs; Research methodology; Risk factors; Schizophrenia; Serum; Studies; Ankara Turkey; Turkey; biomarker; psychosis; neurotrophin
• ISSN: 1176-6328; 1178-2021; 1178-2021
• DOI: 10.2147/NDT.S79444

Brain-derived neurotrophic factor (BDNF) is a well-established neurotrophin that plays a role in the pathophysiology of numerous psychiatric disorders. Many studies have investigated the serum BDNF levels in patients with schizophrenia. However, there are restricted data in the literature that compare the serum BDNF levels in patients with deficit and nondeficit syndromes. In this study, we aimed to compare the serum BDNF levels between schizophrenic patients with deficit or nondeficit syndrome and healthy controls. After fulfilling the inclusion and exclusion criteria, 58 patients with schizophrenia and 36 healthy controls were included in the study. The patients were grouped as deficit syndrome (N=23) and nondeficit syndrome (N=35) according to the Schedule for the Deficit Syndrome. Three groups were compared in terms of the sociodemographic and clinical variants and serum BDNF levels. The groups were similar in terms of age, sex, body mass index, and smoking status. The serum BDNF levels in patients with deficit syndrome were significantly lower than those in healthy controls. In contrast, the serum BDNF levels in patients with nondeficit syndrome were similar to those in healthy controls. This study suggests that decreased BDNF levels may play a role in the pathophysiology of schizophrenic patients with deficit syndrome. Nonetheless, additional studies using a larger patient sample size are needed to investigate the serum BDNF levels in schizophrenic patients with deficit syndrome.